A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
Por:
Zozaya N., Arrizubieta Basterrechea M.I., Bollo E., Castellví I., Espín J., Ortego N., Poveda-Andrés J.L., Rodríguez Portal J.A., Rivero A., Marcos-Rodríguez J.A., Verde L.
Publicada:
1 ago 2022
Ahead of Print:
1 ago 2022
Resumen:
Objectives Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Methods Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. Results The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0.50 ± 0.16, on a scale from -1 to 1) and SSc-ILD (0.40 ± 0.12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0.06-0.07), given its proven clinical efficacy (0.05-0.06), slight improvements in patient-reported outcomes (0.01-0.02), and similar safety profile than placebo (-0.04-0.00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Conclusions Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain. © Author(s).
Filiaciones:
Zozaya N.:
Department of Health Economics, Weber, Madrid, Spain
Department of Quantitative Methods in Economics and Management, University of Las Palmas de Gran Canaria, Las Palmas, Spain
Arrizubieta Basterrechea M.I.:
Department of Pneumology, Hospital Universitario de Galdakao-Usansolo, Bizkaia, Spain
Bollo E.:
Department of Pneumology, Complejo Asistencial Universitario de León, León, Spain
Castellví I.:
Department of Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
Espín J.:
Andalusian School of Public Health, Granada, Spain
Ortego N.:
Unit of Systemic Autoimmune Diseases, Hospital Universitario Clínico San Cecilio, Granada, Spain
Poveda-Andrés J.L.:
Department of Pharmacy, Unit of Clinical Medications, Hospital Universitari i Politècnic la Fe, Valencia, Spain
Rodríguez Portal J.A.:
Department of Pneumology, Hospital Universitario Virgen Del Rocío, Seville, Spain
Centro de Investigación Biomédica en Red - Enfermedades Respiratorias (CIBERES), Madrid, Spain
Rivero A.:
Bioregión de Salud y Bienestar (BioMad), Madrid, Spain
Marcos-Rodríguez J.A.:
Department of Pharmacy, Hospital Universitario Virgen Macarena, Seville, Spain
Verde L.:
Management Department, Integrated Health Area, A Coruña, Spain
All Open Access; Hybrid Gold
|